{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:26:00Z","timestamp":1793467560181,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals 12325Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s12325-020-01314-0","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T10:02:44Z","timestamp":1587636164000},"page":"2050-2070","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The Myeloproliferative Neoplasm Landscape: A Patient\u2019s Eye View"],"prefix":"10.1007","volume":"37","author":[{"given":"Cheryl","family":"Petruk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mathias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"1314_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/03007995.2018.1473245","volume":"34","author":"E Abruzzese","year":"2018","unstructured":"Abruzzese E, Niscola P, Trawinska MM, de Fabritiis P. Chronic myeloproliferative disorders: is quality-of-life the new goal? Curr Med Res Opin. 2018;34:1345\u20137.","journal-title":"Curr Med Res Opin"},{"key":"1314_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1182\/asheducation-2017.1.480","volume":"2017","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Guglielmelli P. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? Hematology Am Soc Hematol Educ Program. 2017;2017:480\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"1314_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients\u2019 overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.","journal-title":"BMC Cancer"},{"key":"1314_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313 (quiz 2615).","journal-title":"Blood"},{"key":"1314_CR5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","volume":"129","author":"AM Vannucchi","year":"2017","unstructured":"Vannucchi AM, Harrison CN. Emerging treatments for classical myeloproliferative neoplasms. Blood. 2017;129:693\u2013703.","journal-title":"Blood"},{"key":"1314_CR6","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ajh.24098","volume":"90","author":"LA Anderson","year":"2015","unstructured":"Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90:864\u201370.","journal-title":"Am J Hematol"},{"key":"1314_CR7","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017;96:1653\u201365.","journal-title":"Ann Hematol"},{"key":"1314_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","volume":"18","author":"R Mesa","year":"2018","unstructured":"Mesa R, Boccia RV, Grunwald MR, et al. Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:590\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1314_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-018-4322-9","volume":"18","author":"J Yu","year":"2018","unstructured":"Yu J, Parasuraman S, Paranagama D, et al. Impact of myeloproliferative neoplasms on patients\u2019 employment status and work productivity in the United States: results from the living with MPNs survey. BMC Cancer. 2018;18:420.","journal-title":"BMC Cancer"},{"key":"1314_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00277-019-03610-4","volume":"98","author":"J Yu","year":"2019","unstructured":"Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey. Ann Hematol. 2019;98:1119\u201325.","journal-title":"Ann Hematol"},{"key":"1314_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/CLEP.S162688","volume":"11","author":"N Brochmann","year":"2018","unstructured":"Brochmann N, Flachs EM, Christensen AI, et al. Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark. Clin Epidemiol. 2018;11:23\u201333.","journal-title":"Clin Epidemiol"},{"key":"1314_CR12","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.psym.2018.01.006","volume":"59","author":"DC McFarland","year":"2018","unstructured":"McFarland DC, Shaffer KM, Polizzi H, et al. Associations of physical and psychologic symptom burden in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Psychosomatics. 2018;59:472\u201380.","journal-title":"Psychosomatics"},{"key":"1314_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1314_CR14","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.","journal-title":"PLoS Med"},{"key":"1314_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391\u2013405.","journal-title":"N Engl J Med"},{"key":"1314_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","volume":"16","author":"G Greenfield","year":"2018","unstructured":"Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018;16:360.","journal-title":"J Transl Med"},{"key":"1314_CR17","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544\u201351.","journal-title":"Blood"},{"key":"1314_CR18","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376:2168\u201381.","journal-title":"N Engl J Med"},{"key":"1314_CR19","first-page":"3","volume":"2","author":"W Alduaji","year":"2018","unstructured":"Alduaji W, McNamara CJ, Schuh A, et al. Clinical utility of next-generation sequencing in the management of myeloproliferative neoplasms: a single-center experience. HemaSphere. 2018;2:3.","journal-title":"HemaSphere"},{"issue":"5","key":"1314_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12032-017-0944-z","volume":"34","author":"YC Chang","year":"2017","unstructured":"Chang YC, Lin HC, Chiang YH, et al. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017;34(5):83.","journal-title":"Med Oncol"},{"issue":"15","key":"1314_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, et al. Disease heterogeneity and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416\u201330.","journal-title":"N Engl J Med"},{"issue":"2","key":"1314_CR22","doi-asserted-by":"publisher","first-page":"a034876","DOI":"10.1101\/cshperspect.a034876","volume":"10","author":"AE Marneth","year":"2020","unstructured":"Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10(2):a034876.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1314_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00277-016-2730-y","volume":"95","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Isfort S, Gattermann N, et al. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Ann Hematol. 2016;95:1399\u2013410.","journal-title":"Ann Hematol"},{"key":"1314_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.leukres.2017.08.002","volume":"61","author":"MH Ellis","year":"2017","unstructured":"Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Ruxolitinib for the management of myelofibrosis: results of an international physician survey. Leuk Res. 2017;61:6\u20139.","journal-title":"Leuk Res"},{"key":"1314_CR25","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.clml.2018.07.297","volume":"19","author":"LA Habib","year":"2019","unstructured":"Habib LA, Kuo KHM, Panzarella T, Gupta V, Trinkaus M. Management of polycythemia vera: a survey of Canadian physician practice patterns. Clin Lymphoma Myeloma Leuk. 2019;19:e37\u201342.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1314_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/cncr.30325","volume":"123","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Miller CB, Thyne M, et al. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey. Cancer. 2017;123:449\u201358.","journal-title":"Cancer"},{"key":"1314_CR27","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Myeloproliferative neoplasms. Version 2.2019\u2013October 29, 2018. 2019. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf. Accessed Aug 2019."},{"key":"1314_CR28","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"issue":"Suppl 5","key":"1314_CR29","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v85\u201399.","journal-title":"Ann Oncol"},{"key":"1314_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bjh.15648","volume":"184","author":"MF McMullin","year":"2019","unstructured":"McMullin MF, Harrison CN, Ali S, et al. A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. Br J Haematol. 2019;184:176\u201391.","journal-title":"Br J Haematol"},{"key":"1314_CR31","unstructured":"Nordic MPN Study Group. Nordic guidelines on the diagnosis and treatment of patients with myeloproliferative neoplasms. 2019. https:\/\/nmpn.org\/index.php\/guidelines\/17-nmpn-care-program-2017\/file. Accessed Mar 2020."},{"key":"1314_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.4103\/ijmpo.ijmpo_88_17","volume":"39","author":"MB Agarwal","year":"2018","unstructured":"Agarwal MB, Malhotra H, Chakrabarti P, et al. Revised myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Indian J Med Paediatr Oncol. 2018;39:503\u201315.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"1314_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s12185-017-2330-1","volume":"106","author":"N Usui","year":"2017","unstructured":"Usui N. JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2017;106:591\u2013611.","journal-title":"Int J Hematol"},{"key":"1314_CR34","doi-asserted-by":"publisher","first-page":"771","DOI":"10.3904\/kjim.2015.30.6.771","volume":"30","author":"CW Choi","year":"2015","unstructured":"Choi CW, Bang SM, Jang S, et al. Guidelines for the management of myeloproliferative neoplasms. Korean J Intern Med. 2015;30:771\u201388.","journal-title":"Korean J Intern Med"},{"key":"1314_CR35","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"1314_CR36","unstructured":"JAKAFI (ruxolitinib) [prescribing information] Wilmington, DE, Incyte Corporation. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202192s017lbl.pdf. Accessed Sep 2019."},{"key":"1314_CR37","unstructured":"INREBIC (fedratinib) [prescribing information]. Summit, NJ, Celgene Corporation. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212327s000lbl.pdf. Accessed Sep 2019."},{"key":"1314_CR38","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"1314_CR39","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"1314_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100:479\u201388.","journal-title":"Haematologica"},{"key":"1314_CR41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017;10:156.","journal-title":"J Hematol Oncol"},{"key":"1314_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","volume":"11","author":"HM Kvasnicka","year":"2018","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis. J Hematol Oncol. 2018;11:42.","journal-title":"J Hematol Oncol"},{"key":"1314_CR43","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1056\/NEJMoa1409002","volume":"372","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426\u201335.","journal-title":"N Engl J Med"},{"key":"1314_CR44","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/ejh.12707","volume":"97","author":"R Mesa","year":"2016","unstructured":"Mesa R, Verstovsek S, Kiladjian JJ, et al. Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Eur J Haematol. 2016;97:192\u2013200.","journal-title":"Eur J Haematol"},{"key":"1314_CR45","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","volume":"97","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018;97:1591\u2013600.","journal-title":"Ann Hematol"},{"issue":"3","key":"1314_CR46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/ajh.24976","volume":"93","author":"F Lussana","year":"2018","unstructured":"Lussana F, Cattaneo M, Rambaldi A, Squizzato A. Ruxolitinib-associated infections: a systematic review and meta-analysis. Am J Hematol. 2018;93(3):339\u201347.","journal-title":"Am J Hematol"},{"issue":"1","key":"1314_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17(1):78.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"1314_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1182\/blood-2017-10-810739","volume":"132","author":"E Porpaczy","year":"2018","unstructured":"Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1\/2 inhibitor therapy. Blood. 2018;132(7):694\u2013706.","journal-title":"Blood"},{"key":"1314_CR49","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1038\/bcj.2014.84","volume":"4","author":"A Pardanani","year":"2014","unstructured":"Pardanani A, Tefferi A. Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J. 2014;4:e268.","journal-title":"Blood Cancer J"},{"key":"1314_CR50","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1182\/blood-2017-04-742288","volume":"130","author":"P Bose","year":"2017","unstructured":"Bose P, Verstovsek S. JAK2 inhibitors for myeloproliferative neoplasms: what is next? Blood. 2017;130:115\u201325.","journal-title":"Blood"},{"key":"1314_CR51","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 2015;1:643\u201351.","journal-title":"JAMA Oncol"},{"key":"1314_CR52","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4:e317\u2013e324.","journal-title":"Lancet Haematol"},{"key":"1314_CR53","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","volume":"35","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis. J Clin Oncol. 2017;35:3844\u201350.","journal-title":"J Clin Oncol"},{"key":"1314_CR54","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","volume":"5","author":"CN Harrison","year":"2018","unstructured":"Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018;5:e73\u201381.","journal-title":"Lancet Haematol"},{"key":"1314_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41408-018-0067-6","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Barraco D, Lasho TL, et al. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Blood Cancer J. 2018;8:29.","journal-title":"Blood Cancer J"},{"key":"1314_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.leukres.2017.05.002","volume":"60","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Courby S, Griesshammer M, et al. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Leuk Res. 2017;60:11\u20137.","journal-title":"Leuk Res"},{"key":"1314_CR57","unstructured":"Sierra Oncology. Sierra announces momelotinib granted FDA fast track designation. Press release. 2019. https:\/\/investor.sierraoncology.com\/2019-06-05-Sierra-Announces-Momelotinib-Granted-FDA-Fast-Track-Designation. Accessed Sep 2019."},{"key":"1314_CR58","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","volume":"4","author":"J Mascarenhas","year":"2018","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. JAMA Oncol. 2018;4:652\u20139.","journal-title":"JAMA Oncol"},{"key":"1314_CR59","doi-asserted-by":"publisher","first-page":"LBA-5","DOI":"10.1182\/blood.V128.22.LBA-5.LBA-5","volume":"128","author":"J Mascarenhas","year":"2016","unstructured":"Mascarenhas J, Hoffman R, Talpaz M, et al. Results of the persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) l and platelet counts <100,000\/\u00b5l. Blood. 2016;128:LBA-5.","journal-title":"Blood"},{"key":"1314_CR60","unstructured":"CTI BioPharma. CTI BioPharma announces removal of full clinical hold on pacritinib. Press release. 2019. https:\/\/cbc.gcs-web.com\/news-releases\/news-release-details\/cti-biopharma-announces-removal-full-clinical-hold-pacritinib. Accessed Sep 2019."},{"key":"1314_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3324\/haematol.2016.149559","volume":"102","author":"HL Geyer","year":"2017","unstructured":"Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017;102:85\u201393.","journal-title":"Haematologica"},{"key":"1314_CR62","unstructured":"Sunder RA. Financial toxicity: a growing burden for cancer patients. Bulletin American College Surgeons. 2019. https:\/\/bulletin.facs.org\/2019\/09\/financial-toxicity-a-growing-burden-for-cancer-patients\/. Accessed Dec 2019."},{"issue":"23","key":"1314_CR63","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1182\/blood.V126.23.5561.5561","volume":"126","author":"SV Parasuraman","year":"2015","unstructured":"Parasuraman SV, Naim AB, Paranagama DC, et al. Financial burden of myeloproliferative neoplasms on patients: results from the MPN Landmark survey in the United States. Blood. 2015;126(23):5561.","journal-title":"Blood"},{"key":"1314_CR64","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/cncr.28631","volume":"120","author":"DP Steensma","year":"2014","unstructured":"Steensma DP, Komrokji RS, Stone RM, et al. Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes. Cancer. 2014;120:1670\u20136.","journal-title":"Cancer"},{"key":"1314_CR65","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1097\/NCC.0b013e318269040f","volume":"36","author":"C Xiao","year":"2013","unstructured":"Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs. 2013;36:E1\u2013E16.","journal-title":"Cancer Nurs"},{"key":"1314_CR66","unstructured":"MPN Research Foundation. Off-label drugs and the compendia. 2019. https:\/\/www.mpnresearchfoundation.org\/Drug-Reimbursement. Accessed Sep 2019."},{"key":"1314_CR67","doi-asserted-by":"crossref","unstructured":"Drain PK, Parker RA, Robine M, Holmes KK, Bassett IV. Global migration of clinical research during the era of trial registration. PLoS One. 2018;13:e0192413 (Erratum in: PLoS One. 2018;13:e0199952).","DOI":"10.1371\/journal.pone.0199952"},{"key":"1314_CR68","unstructured":"ClinicalTrails.gov. Locations of registered studies. 2019. https:\/\/clinicaltrials.gov\/ct2\/resources\/trends#LocationsOfRegisteredStudies. Accessed Sep 2019."},{"key":"1314_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nrneph.2015.6","volume":"11","author":"IG Okpechi","year":"2015","unstructured":"Okpechi IG, Swanepoel CR, Venter F. Access to medications and conducting clinical trials in LMICs. Nat Rev Nephrol. 2015;11:189\u201394.","journal-title":"Nat Rev Nephrol"},{"key":"1314_CR70","unstructured":"NHS Cancer Patient Experience Survey 2011\/12 National Report. 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/212860\/Cancer-Patient-Experience-Survey-National-Report-2011-12.pdf. Accessed Sep 2019."},{"key":"1314_CR71","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMra1510059","volume":"375","author":"I Ford","year":"2016","unstructured":"Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375:454\u201363.","journal-title":"N Engl J Med"},{"key":"1314_CR72","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.clinthera.2017.03.018","volume":"39","author":"IB Hirsch","year":"2017","unstructured":"Hirsch IB, Martinez J, Dorsey ER, et al. Incorporating site-less clinical trials into drug development: a framework for action. Clin Ther. 2017;39:1064\u201376.","journal-title":"Clin Ther"},{"key":"1314_CR73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401\u20138.","journal-title":"Blood"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01314-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T15:13:54Z","timestamp":1650554034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01314-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01314-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}